GLIPR2 and cancer: The derived outcomes revealed a prevailing downregulation of GLIPR2 across a spectrum of cancers (Figure 2C), inclusive of but not limited to bladder urothelial carcinoma (BLCA), breast invasive carcinoma (BRCA), colon adenocarcinoma (COAD), kidney chromophobe (KICH), LUAD, LUSC, pancreatic adenocarcinoma (PAAD), prostate adenocarcinoma (PRAD), CESC, and rectum adenocarcinoma (READ).